Compare Abbott Laboratories (ABT) vs ArcelorMittal SA (MT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ArcelorMittal SA — how do they compare? Abbott Laboratories trades at $95.15 (market cap $166.94B), while ArcelorMittal SA trades at $62.72 (market cap $48.35B). The key difference: Abbott Laboratories is far larger — about 3.5× ArcelorMittal SA's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MT | |
|---|---|---|
Market Cap | $166.94B | $48.35B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $71.65 |
52-Week Low | $82.57 | $30.39 |
Enterprise Value | $193.69B | $57.67B |
Dividend Yield | 2.63% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ArcelorMittal (MT) trades at $63.15, down 0.39% on the day, with a bullish technical signal supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.11 and P/S of 0.81. Recent news highlights expansion initiatives, a share buyback program, and a strategic AI collaboration with AWS to drive efficiency and lower-carbon steel production.
The outlook for MT is positive, driven by operational expansions and favorable steel import policies in Europe and the US, though risks include high capital expenditures and exposure to Chinese market weakness. Analyst sentiment is predominantly bullish with 50% buy ratings, supporting potential upside if earnings growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
